國藥科技股份(08156.HK)：國科防偽創新型防偽產品商業合作平均每年達1700萬個
格隆匯9月27日丨國藥科技股份(08156.HK)發佈公吿，截至該公吿日，集團就提供國科防偽創新型防偽產品(“國科防偽創新型防偽產品”)所簽訂的商業合作數量平均每年約1700萬個。近期公司的直接全資附屬公司——深圳國科防偽科技有限公司(“國科防偽”)與青海青藏蜜蜂良種養殖場(“青海藏蜜”)簽署商業合同，向青海藏蜜全線產品提供國科防偽創新型防偽產品。至此，與國科防偽訂立商業協議的企業用户所處行業已從過往茶葉、天然食品及美粧電商擴展覆蓋至健康食品行業。國科防偽向該等企業用户旗下產品提供國科防偽創新型防偽產品，為其提供創新的產品防偽及同時實現產品營銷及公益功能。國科防偽創新型防偽產品中防偽科技＋互動營銷的理念既能為品牌聲譽保駕護航，又為品牌商鞏固其消費羣體。未來國科防偽創新型防偽產品將繼續覆蓋至更多行業的不同產品，提供防偽、營銷及公益於一體的新零售解決方案。
國科防偽創新型防偽產品採用防偽包裝裝置與彩票結合的技術，可通過客製化設計與不同的消費品融合，產品具備四大特性—“防偽”、“公信力”、“社會責任”及“營銷”。國科防偽創新型防偽產品的獨有元素以及兑獎設置，鼓勵消費者主動參與驗真，形成驗真習慣，維護自身權益；營銷功能對銷量的刺激作用，達至品牌商家與消費者雙贏。
隨着品牌企業越來越重視維護產品和品牌的完整性，以及政府實施更為嚴格的防偽法律法規，產品防偽認證和品牌保護市場正快速增長，消費者對正品商品需求的重視程度提高亦為防偽認證和品牌保護市場創造機會。截至目前，集團防偽業務完成從獲取專利技術授權、與各供應商連接生產流程、拓展客源到成品落地的全環節建設，防偽整體解決方案閉環現已成型。董事會認為，集團防偽業務在行業應用探索中再進一步，同時將日趨成熟的業務模式透過公司在不同地區的資源及營運體系複製至更廣泛的應用中，與不同企業用户的合作將繼續加強國科防偽創新型防偽產品的品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
